HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of Linagliptin on Vessel Wall Healing in the Rat Model of Arterial Injury Under Normal and Diabetic Conditions.

Abstract
Diabetic patients suffer an increased risk of restenosis and late stent thrombosis after angioplasty, complications which are related to a defective reendothelialization. Dipeptidyl peptidase-4 inhibitors have been suggested to exert a direct effect on endothelial and smooth muscle cells (SMCs). Therefore, the objective was to study if the dipeptidyl peptidase-4 inhibitor linagliptin could influence vascular repair and accelerate reendothelialization after arterial injury in healthy and diabetic animals. Diabetic Goto-Kakizaki and healthy Wistar rats were subjected to arterial injury and treated with linagliptin or vehicle. Vessel wall healing was monitored noninvasively using ultrasound, and on sacrifice, with Evans blue staining and immunohistochemistry. The effect of linagliptin on SMCs was also studied in vitro. We found that linagliptin reduced the proliferation and dedifferentiation of SMCs in vitro, and modulated the inflammatory response in the SMCs after arterial injury in vivo. However, these effects of linagliptin did not affect the neointima formation or the reendothelialization under normal and diabetic conditions. Although linagliptin did not influence vessel wall healing, it seems to possess a desirable antiproliferative influence on SMCs in vitro and an antiinflammatory effect in vivo. These pharmacological properties might carry a potential significance for favorable outcome after vascular interventions in diabetic patients.
AuthorsLinnea Eriksson, Samuel Röhl, Robert Saxelin, Mariette Lengquist, Malin Kronqvist, Kenneth Caidahl, Claes-Göran Östenson, Anton Razuvaev
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 69 Issue 2 Pg. 101-109 (Feb 2017) ISSN: 1533-4023 [Electronic] United States
PMID27875385 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Blood Glucose
  • Hypoglycemic Agents
  • Linagliptin
Topics
  • Animals
  • Blood Glucose (drug effects, metabolism)
  • Carotid Artery Injuries (blood, drug therapy)
  • Carotid Artery, External (drug effects, metabolism)
  • Cell Proliferation (drug effects, physiology)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Dose-Response Relationship, Drug
  • Hypoglycemic Agents (pharmacology, therapeutic use)
  • Linagliptin (pharmacology, therapeutic use)
  • Male
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Treatment Outcome
  • Wound Healing (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: